GPT and fibrosis: The non-patented fibrosis-4 (FIB-4) test which includes age, platelets, and liver enzymes (alanine aminotransferase, ALT; aspartate aminotransferase, AST) has been recommended as screening instrument to identify patients with CLD in the out-patient setting, while the patented Enhanced Liver FibrosisTM (ELFTM) test was suggested to be used as an instrument to confirm advanced fibrosis or cirrhosis in patients with intermediate to high risk (i.e., VCTE ≥ 8 kPa) [8].